What is the recommended initiation and maintenance dose of tolvaptan for adults ≤55 years with autosomal dominant polycystic kidney disease, estimated glomerular filtration rate ≥25 mL/min/1.73 m² and rapid disease progression?

Tolvaptan Dosing for ADPKD

Start tolvaptan at 45 mg upon waking and 15 mg eight hours later, then titrate weekly to a target dose of 90 mg in the morning and 30 mg in the afternoon if tolerated. 1

Initial Dosing Protocol

• Begin with 45 mg in the morning upon waking, followed by 15 mg eight hours later 1, 2
• This split-dose regimen minimizes nocturnal polyuria while maintaining therapeutic effect throughout the day 3

Titration Schedule

• Increase the dose after at least 1 week if the initial dose is well-tolerated 1

• The titration follows a clear three-step approach: 1

  • Week 1+: 45 mg morning / 15 mg afternoon (60 mg total daily)
  • Week 2+: 60 mg morning / 30 mg afternoon (90 mg total daily)
  • Week 3+: 90 mg morning / 30 mg afternoon (120 mg total daily) - target dose

• The target maintenance dose is 90 mg in the morning and 30 mg in the afternoon 1, 2

• Higher doses show dose-dependent efficacy, so reaching the maximum tolerated dose should be prioritized if the patient tolerates it 4

Duration of Treatment

• Continue tolvaptan until approaching kidney replacement therapy if well-tolerated 1, 2
• Treatment can be continued even when eGFR falls below 25 mL/min/1.73 m² if the patient tolerates it 1, 2
• Treatment can also be continued in patients aged >55 years if well-tolerated 1, 2

Critical Monitoring Requirements

Hepatotoxicity Surveillance

• Perform liver function tests monthly for the first 18 months, then every 3 months thereafter until drug discontinuation 1, 2
• Obtain morning blood samples before the tolvaptan dose 1
• Permanently discontinue if ALT or AST increase to ≥3× upper limit of normal (ULN) 1, 2
• Discontinue if ALT or AST >2× ULN with signs/symptoms of liver injury 1

Fluid and Electrolyte Management

• Monitor serum sodium to assess adequacy of water intake, using morning samples before the tolvaptan dose 1
• Patients must drink enough water to replace urinary losses, typically 2-3 liters per day 1, 2
• Counsel patients to drink liquids without sugar or fat and adopt low-sodium intake (<2000 mg/day) to reduce polyuria 1, 5

Dose Adjustments and Special Situations

• Consider downtitration for: 2
  • Concurrent CYP3A inhibitor use (avoid strong and moderate inhibitors including antifungals, antibiotics, protease inhibitors, and grapefruit juice) 2
  • Intolerance or side effects (aquaresis-related effects like polyuria, thirst, dry mouth) 2
  • Elevated liver enzymes 2

Common Pitfalls to Avoid

• Inadequate fluid counseling: Patients must understand the need for 2-3 liters daily water intake to prevent hypernatremia 1
• Missing the sick-day plan: Temporarily discontinue during acute illness that could precipitate dehydration or acute kidney injury 1
• Insufficient monitoring: Failure to perform monthly LFTs in the first 18 months is a critical safety oversight 1
• Ignoring drug interactions: CYP3A inhibitors can significantly increase tolvaptan levels and toxicity risk 2
• Premature discontinuation: Aquaresis side effects often improve with time and fluid management strategies; don't stop too early 1

Efficacy Expectations

• Tolvaptan reduces the annual rate of eGFR decline by approximately 1.0-1.3 mL/min/1.73 m² per year compared to placebo 2, 5
• It decreases total kidney volume growth by 2.7% compared to placebo 2
• The weight-adjusted average daily dose significantly affects the change in eGFR, supporting maximization of dose when tolerated 4